Mozart Therapeutics to Present MTX-101 at 2024 ADA Scientific Sessions

Mozart Therapeutics, a biopharmaceutical company specializing in CD8 Treg modulators for autoimmune diseases, unveiled new preclinical data on their lead program, MTX-101, at the 2024 American Diabetes Association 84th Scientific Sessions in Orlando, FL. The data were presented by Courtney Crane, Ph.D., Senior Vice President of Research at Mozart Therapeutics.

Dr. Crane's presentation highlighted the therapeutic potential of modulating regulatory CD8 T cells in autoimmune diseases, including type 1 diabetes (T1D). The preclinical data demonstrated that MTX-101 treatment increases the prevalence of CD8 Treg cells and restores their functionality—specifically their activation and cytolytic capacity—in an autoimmune context using T1D-derived PBMC samples.

Dr. Crane noted the significance of these findings in type 1 diabetes, underscoring MTX-101's ability to restore CD8 Treg function in autoimmune diseases. She expressed anticipation for the ongoing Phase 1 study, particularly Part B, which will evaluate MTX-101 in patients with type 1 diabetes mellitus.

MTX-101 is a bispecific antibody that targets inhibitory KIR and CD8 expressed on regulatory CD8 T cells. This innovative autoimmune checkpoint inhibitor is designed to restore the natural functions of CD8 Treg cells. By acting early in the autoimmune disease process, MTX-101 aims to suppress and eliminate pathogenic cells, mitigate downstream inflammation, and prevent tissue damage.

Currently, MTX-101 is under investigation in a randomized, blinded, placebo-controlled Phase 1 clinical trial (NCT06324604). The trial includes two parts: Part A involves healthy adults, while Part B focuses on patients with celiac disease or type 1 diabetes mellitus.

Mozart Therapeutics is dedicated to developing first-in-class therapies aimed at modifying autoimmune diseases by restoring immune system function through the CD8 T regulatory network. The company, based in Seattle, WA, continues to explore innovative treatments to address unmet medical needs in autoimmune conditions.